BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
Rhea-AI Summary
BridgeBio (Nasdaq: BBIO) will report its fourth quarter and full year 2025 financial results and provide a business update after market close on February 24, 2026. The company will host a conference call and live webcast at 4:30 pm ET the same day. A replay will be available on the investor website for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – BBIO
On the day this news was published, BBIO gained 0.80%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peer moves are mixed, with BMRN (-0.12), IONS (-0.71), ASND (-0.7) down while EXEL (2.4) and SMMT (1.49) are up, suggesting stock-specific positioning into BridgeBio’s earnings date rather than a clear sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 12 | Phase 3 clinical data | Positive | +3.7% | Positive Phase 3 PROPEL 3 topline results in achondroplasia. |
| Jan 27 | Inducement equity grants | Neutral | -0.5% | Nasdaq Rule 5635(c)(4) inducement RSU grants to new employees. |
| Jan 27 | Inducement equity grants | Neutral | -0.5% | Additional RSU inducement awards under 2019 Inducement Equity Plan. |
| Jan 16 | Convertible notes pricing | Neutral | +0.0% | Pricing of $550M 0.75% convertible notes due 2033 to manage 2027 notes. |
| Jan 14 | Convertible notes offering | Neutral | -2.1% | Proposed $550M convertible notes offering and share repurchase plan. |
Recent news has combined positive clinical data, balance sheet management, and routine equity/inducement activity, with generally modest single-day price reactions.
Over the past months, BridgeBio has reported several notable developments. On Jan 12, 2026, it shared positive preliminary 2025 figures, including net product revenue of $146.0 million for Q4 and $362.4 million for full-year 2025, plus cash and equivalents of $587.5 million. The company also executed a $632.5 million convertible notes offering to refinance 2027 notes and repurchased over 1.0 million shares. More recently, it announced positive Phase 3 PROPEL 3 results. Today’s earnings date notice follows these updates and sets the timeline for full audited numbers and a broader business review.
Market Pulse Summary
This announcement sets the timetable for BridgeBio’s detailed discussion of its fourth quarter and full-year 2025 performance, with a call on February 24, 2026 at 4:30 pm ET. Investors already have preliminary figures from January, including cash of $587.5 million and full-year net product revenue of $362.4 million. The upcoming call will contextualize recent Phase 3 results, balance sheet actions like the $632.5 million convertible notes, and program updates, making management’s commentary and any updated outlook key metrics to watch.
AI-generated analysis. Not financial advice.
PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its fourth quarter and full year 2025 financial results and business updates after the market closes on Tuesday, February 24, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day.
To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
Participants may access the webcast by registering online using the following link, here.
About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.
BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com
FAQ
When will BridgeBio (BBIO) report Q4 and full year 2025 results?
How can I access BridgeBio's (BBIO) February 24, 2026 webcast and conference call?
Will a replay of the BridgeBio (BBIO) February 24, 2026 presentation be available?
What topics will BridgeBio (BBIO) cover during the February 24, 2026 call?
What time is the BridgeBio (BBIO) earnings call on February 24, 2026 and which time zone?
